NO20000396L - Katalytiske monoklonale antistoffer med protease-aktivitet for selektiv lysis av proteinkomponenten hos plakker og aggregater relatert til patologiske tilstander - Google Patents
Katalytiske monoklonale antistoffer med protease-aktivitet for selektiv lysis av proteinkomponenten hos plakker og aggregater relatert til patologiske tilstanderInfo
- Publication number
- NO20000396L NO20000396L NO20000396A NO20000396A NO20000396L NO 20000396 L NO20000396 L NO 20000396L NO 20000396 A NO20000396 A NO 20000396A NO 20000396 A NO20000396 A NO 20000396A NO 20000396 L NO20000396 L NO 20000396L
- Authority
- NO
- Norway
- Prior art keywords
- plaques
- monoclonal antibodies
- protease activity
- protein component
- pathological conditions
- Prior art date
Links
- 108091005804 Peptidases Proteins 0.000 title abstract 2
- 239000004365 Protease Substances 0.000 title abstract 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 title abstract 2
- 230000003197 catalytic effect Effects 0.000 title abstract 2
- 230000000694 effects Effects 0.000 title abstract 2
- 235000004252 protein component Nutrition 0.000 title abstract 2
- 230000009089 cytolysis Effects 0.000 title 1
- 230000001575 pathological effect Effects 0.000 title 1
- 230000007170 pathology Effects 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 102000029797 Prion Human genes 0.000 abstract 1
- 108091000054 Prion Proteins 0.000 abstract 1
- 206010002022 amyloidosis Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0002—Antibodies with enzymatic activity, e.g. abzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT97MI001826A IT1293511B1 (it) | 1997-07-30 | 1997-07-30 | Anticorpi monoclonali catalitici ad attivita' proteasica per la lisi selettiva della componente proteica di placche e aggregati correlati |
PCT/EP1998/004706 WO1999006066A2 (en) | 1997-07-30 | 1998-07-28 | Catalytic monoclonal antibodies with protease activity for the selective lysis of the protein component of plaques and aggregates related to pathological conditions |
Publications (3)
Publication Number | Publication Date |
---|---|
NO20000396D0 NO20000396D0 (no) | 2000-01-26 |
NO20000396L true NO20000396L (no) | 2000-03-29 |
NO329769B1 NO329769B1 (no) | 2010-12-13 |
Family
ID=11377678
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20000396A NO329769B1 (no) | 1997-07-30 | 2000-01-26 | Katalytiske monoklonale antistoffer med protease-aktivitet for selektiv lysis av proteinkomponenten hos plakker og aggregater relatert til patologiske tilstander |
Country Status (17)
Country | Link |
---|---|
US (1) | US6387674B1 (no) |
EP (1) | EP0996463B1 (no) |
JP (1) | JP2001511369A (no) |
CN (1) | CN1268175A (no) |
AT (1) | ATE466883T1 (no) |
AU (1) | AU741368B2 (no) |
CA (1) | CA2299442C (no) |
CY (1) | CY1110128T1 (no) |
DE (1) | DE69841653D1 (no) |
DK (1) | DK0996463T3 (no) |
ES (1) | ES2340892T3 (no) |
IL (1) | IL134142A0 (no) |
IT (1) | IT1293511B1 (no) |
NO (1) | NO329769B1 (no) |
NZ (1) | NZ502527A (no) |
PT (1) | PT996463E (no) |
WO (1) | WO1999006066A2 (no) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6905686B1 (en) | 1997-12-02 | 2005-06-14 | Neuralab Limited | Active immunization for treatment of alzheimer's disease |
US6787523B1 (en) | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US20030147882A1 (en) | 1998-05-21 | 2003-08-07 | Alan Solomon | Methods for amyloid removal using anti-amyloid antibodies |
US6787637B1 (en) | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
US6582945B1 (en) | 1999-06-16 | 2003-06-24 | Boston Biomedical Research Institute | Immunological control of β-amyloid levels in vivo |
BR0108566A (pt) * | 2000-02-21 | 2002-11-19 | Pharmexa As | Método para a regulação negativa in vivo de proteìna amilóide em um animal, incluindo um ser humano e para o tratamento e/ou prevenção e/ou melhora da doença de alzheimer ou outras doenças e condições cartacterizadas por depósitos de amilóide, análogo de um polipeptìdeo amiloidogênico,composição imunogênica, fragmento de ácido nucleico, vetor, célula transformada, composição para induzir a produção de anticorpos contra um polipeptìdeo amiloidogênico, linhagem celular estável, métodos para a preparação de uma célula, para a identificação de um polipeptìdeo amiloidogênico modificado, e para preparação de uma composição imunogênica, uso de um polipeptìdeo amiloidogênico ou de uma subsequência do mesmo, e, uso de um análogo de um polipeptìdeo amiloidogênico |
EP1481992B1 (en) | 2000-02-24 | 2016-11-02 | Washington University St. Louis | Humanized antibodies that sequester amyloid beta peptide |
US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
US6613505B2 (en) | 2001-04-12 | 2003-09-02 | Bioresource International, Inc. | Composition and method for destruction of infetious prion proteins |
DE60230736D1 (de) | 2001-04-30 | 2009-02-26 | Lilly Co Eli | HUMANISIERTE ANTIKÖRPER DIE DAS BETA-AMYLOID PEPTID ERKENNEN& x9; |
AU2002257162A1 (en) | 2001-04-30 | 2002-11-11 | Eli Lilly And Company | Humanized antibodies |
ES2391905T3 (es) | 2001-08-17 | 2012-11-30 | Washington University | Método de ensayo para la enfermedad de alzheimer |
MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
EP1596809B1 (en) | 2003-02-10 | 2010-05-26 | Applied Molecular Evolution, Inc. | Abeta binding molecules |
TWI306458B (en) | 2003-05-30 | 2009-02-21 | Elan Pharma Int Ltd | Humanized antibodies that recognize beta amyloid peptide |
TW200635607A (en) | 2004-12-15 | 2006-10-16 | Elan Pharm Inc | Humanized Aβ antibodies for use in improving cognition |
PL2289909T3 (pl) | 2005-11-30 | 2015-04-30 | Abbvie Inc | Sposób przeszukiwania, proces oczyszczania niedyfundujących oligomerów Abeta, selektywne przeciwciała przeciw niedyfundującym oligomerom Abeta i sposób wytwarzania tych przeciwciał |
RU2432362C2 (ru) | 2005-11-30 | 2011-10-27 | Эбботт Лэборетриз | Моноклональные антитела и их применения |
CA2632822C (en) * | 2005-12-12 | 2018-08-28 | Ruth Greferath | A beta 1-42 specific monoclonal antibodies with therapeutic properties |
US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
EP2046833B9 (en) | 2006-07-14 | 2014-02-19 | AC Immune S.A. | Humanized antibody against amyloid beta |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
BRPI0806715A2 (pt) | 2007-01-18 | 2011-09-13 | Lilly Co Eli | fab peguilado para abeta |
EP2486928A1 (en) | 2007-02-27 | 2012-08-15 | Abbott GmbH & Co. KG | Method for the treatment of amyloidoses |
US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
MX2009013505A (es) * | 2007-06-12 | 2010-01-27 | Ac Immune Sa | Anticuerpos humanizados para amiloide beta. |
US8048420B2 (en) * | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
ES2498040T3 (es) | 2007-07-27 | 2014-09-24 | Janssen Alzheimer Immunotherapy | Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados |
CN101883790B (zh) * | 2007-10-05 | 2015-09-09 | 基因技术公司 | 抗淀粉样蛋白β抗体在眼病中的用途 |
WO2009048538A2 (en) * | 2007-10-05 | 2009-04-16 | Genentech, Inc. | Humanized antibody |
JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
US8501178B2 (en) | 2008-11-25 | 2013-08-06 | Biogen Idec Ma Inc. | Use of DR6 and p75 antagonists to promote survival of cells of the nervous system |
US8430831B2 (en) * | 2009-02-25 | 2013-04-30 | The Invention Science Fund I, Llc | Device, system, and method for controllably reducing inflammatory mediators in a subject |
US8317737B2 (en) * | 2009-02-25 | 2012-11-27 | The Invention Science Fund I, Llc | Device for actively removing a target component from blood or lymph of a vertebrate subject |
US8246565B2 (en) * | 2009-02-25 | 2012-08-21 | The Invention Science Fund I, Llc | Device for passively removing a target component from blood or lymph of a vertebrate subject |
MX2012005464A (es) | 2009-11-12 | 2012-06-08 | Genentech Inc | Un metodo para promover la densidad de espinas dendriticas. |
EP2558494B1 (en) | 2010-04-15 | 2018-05-23 | AbbVie Inc. | Amyloid-beta binding proteins |
AU2011282536B2 (en) | 2010-07-30 | 2015-12-24 | Ac Immune S.A. | Safe and functional humanized anti beta-amyloid antibody |
CN103298833B (zh) | 2010-08-14 | 2015-12-16 | Abbvie公司 | β淀粉样蛋白结合蛋白 |
NZ631565A (en) | 2012-03-14 | 2016-07-29 | Regeneron Pharma | Multispecific antigen-binding molecules and uses thereof |
SG10202112460VA (en) | 2015-07-06 | 2021-12-30 | Regeneron Pharma | Multispecific antigen-binding molecules and uses thereof |
EP3448891A1 (en) | 2016-04-28 | 2019-03-06 | Regeneron Pharmaceuticals, Inc. | Methods of making multispecific antigen-binding molecules |
BR112019025888A2 (pt) | 2017-06-07 | 2020-06-30 | Regeneron Pharmaceuticals, Inc. | polinucleotídeo que codifica uma proteína terapêutica multidomínio, vetor de terapia gênica, proteína terapêutica multidomínio recombinante, método de expressão, métodos para reduzir o acúmulo de glicogênio em um tecido em um paciente em necessidade, para reduzir o acúmulo de glicogênio em um tecido em um paciente em necessidade epara tratar a deficiência enzimática em um paciente em necessidade e/ou tolerar o paciente à enzima para a qual é deficiente, anticorpo anti-cd63 ou fragmento de ligação a antígeno, e, composição farmacêutica |
WO2019212965A1 (en) | 2018-04-30 | 2019-11-07 | Regeneron Pharmaceuticals, Inc. | Antibodies, and bispecific antigen-binding molecules that bind her2 and/or aplp2, conjugates, and uses thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA893284B (en) | 1988-05-04 | 1990-03-28 | Igen Inc | Peptide analogs and their use as haptens to elicit catalytic antibodies |
US5318897A (en) * | 1989-04-25 | 1994-06-07 | Igen, Inc. | Monoclonal antibody and antibody components elicited to a polypeptide antigen ground state |
US5258289A (en) * | 1990-09-05 | 1993-11-02 | Davis Claude G | Method for the selecting of genes encoding catalytic antibodies |
CN1165344C (zh) * | 1995-07-21 | 2004-09-08 | 内布拉斯卡大学评议会 | 用于催化水解HIVgp120的组合物及其制备方法和用途 |
-
1997
- 1997-07-30 IT IT97MI001826A patent/IT1293511B1/it active IP Right Grant
-
1998
- 1998-07-28 US US09/463,724 patent/US6387674B1/en not_active Expired - Fee Related
- 1998-07-28 NZ NZ502527A patent/NZ502527A/xx unknown
- 1998-07-28 WO PCT/EP1998/004706 patent/WO1999006066A2/en active IP Right Grant
- 1998-07-28 AU AU92553/98A patent/AU741368B2/en not_active Ceased
- 1998-07-28 CN CN98808388A patent/CN1268175A/zh active Pending
- 1998-07-28 DE DE69841653T patent/DE69841653D1/de not_active Expired - Lifetime
- 1998-07-28 DK DK98945101.8T patent/DK0996463T3/da active
- 1998-07-28 AT AT98945101T patent/ATE466883T1/de not_active IP Right Cessation
- 1998-07-28 PT PT98945101T patent/PT996463E/pt unknown
- 1998-07-28 CA CA2299442A patent/CA2299442C/en not_active Expired - Fee Related
- 1998-07-28 ES ES98945101T patent/ES2340892T3/es not_active Expired - Lifetime
- 1998-07-28 EP EP98945101A patent/EP0996463B1/en not_active Expired - Lifetime
- 1998-07-28 IL IL13414298A patent/IL134142A0/xx not_active IP Right Cessation
- 1998-07-28 JP JP2000504877A patent/JP2001511369A/ja active Pending
-
2000
- 2000-01-26 NO NO20000396A patent/NO329769B1/no not_active IP Right Cessation
-
2010
- 2010-06-03 CY CY20101100487T patent/CY1110128T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
ES2340892T3 (es) | 2010-06-10 |
EP0996463B1 (en) | 2010-05-05 |
EP0996463A2 (en) | 2000-05-03 |
ITMI971826A1 (it) | 1999-01-30 |
CY1110128T1 (el) | 2015-01-14 |
DK0996463T3 (da) | 2010-08-09 |
DE69841653D1 (de) | 2010-06-17 |
WO1999006066A3 (en) | 1999-04-29 |
IL134142A0 (en) | 2001-04-30 |
WO1999006066A2 (en) | 1999-02-11 |
NO20000396D0 (no) | 2000-01-26 |
US6387674B1 (en) | 2002-05-14 |
CN1268175A (zh) | 2000-09-27 |
ATE466883T1 (de) | 2010-05-15 |
NZ502527A (en) | 2003-01-31 |
JP2001511369A (ja) | 2001-08-14 |
CA2299442C (en) | 2011-06-21 |
IT1293511B1 (it) | 1999-03-01 |
AU741368B2 (en) | 2001-11-29 |
AU9255398A (en) | 1999-02-22 |
NO329769B1 (no) | 2010-12-13 |
CA2299442A1 (en) | 1999-02-11 |
PT996463E (pt) | 2010-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20000396L (no) | Katalytiske monoklonale antistoffer med protease-aktivitet for selektiv lysis av proteinkomponenten hos plakker og aggregater relatert til patologiske tilstander | |
DE69918222D1 (de) | Intranasale Zubereitungen zur Behandlung sexueller Störungen | |
ATE385806T1 (de) | Fusionsproteine | |
WO2003039454A3 (en) | Beta-secretase inhibitors and methods of use | |
WO2001083782A3 (en) | Novel proteases | |
ATE262331T1 (de) | Heterocyclische vinylether zur behandlung neurologischer krankheiten | |
EA200100524A1 (ru) | Амиды антраниловой кислоты и их применение в качестве лекарственных средств | |
DE60218493D1 (de) | Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten | |
FI20115753A (fi) | Farmaseuttisia koostumuksia IL-6:n tuoton aiheuttamien sairauksien hoitoon | |
ATE308997T1 (de) | Mittel zur behandlung von erkrankungen der speiseröhre | |
NO20030443D0 (no) | Fremgangsmåte for fremstilling av funksjonelle proteindomener | |
ATE422498T1 (de) | Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems | |
NO994858D0 (no) | Forbindelser og preparater til behandling av sykdommer assosiert med serinprotease, spesielt tryptase aktivitet | |
ATE385517T1 (de) | Interferon ähnliche moleküle, und deren verwendungen | |
DE60024997D1 (de) | Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen | |
DE69735417D1 (de) | 2,5-dihydroxybenzylsulfonderivate zur behandlung von sexuellen störungen | |
NO993653L (no) | FremgangsmÕte for diagnose, prognose og behandling av glaukom og relaterte sykdommer | |
DE60005685D1 (de) | Oxazinocarbazole zur behandlung von cns-erkrankungen | |
PT1196188E (pt) | Anticorpos monoclonais selectivos para o fcv e sua utilizacao para o tratamento de doencas associadas ao fcv | |
DE50010525D1 (de) | Verfahren zur isolierung und aufreinigung von gräserpollenallergenen | |
DE69722178D1 (de) | Therapeutischer wirkstoff für augenerkrankungen | |
HUP0203689A2 (hu) | Interleukin-1 receptor antagonistaszerű molekulák és ezek használata | |
WO2001016319A3 (en) | Compositions and methods for the treatment of immune related diseases | |
ATE224730T1 (de) | Mittel zur behandlung von pigmentierungsstörungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |